Company Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 08:08:19 06/03/2026 GMT			5-day change	1st Jan Change
11.88 ^HKD	+4.76%		-6.53%	-8.69%

03-04	Abbisko Doses First Patient in Tumor Drug Trial	MT
03-03	Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share	RE

Business description: Abbisko Cayman Limited

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâ€™s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Number of employees: 226

Sales by Activity: Abbisko Cayman Limited

Fiscal Period: December	2020 (CNY)	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)
Development of Innovative Medicines	7.3M	22.68M	-	19.06M	504M

See all business segments

Geographical breakdown of sales: Abbisko Cayman Limited

Fiscal Period: December	2020 (CNY)	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)
Mainland China	7.3M	22.68M	-	19.06M	504M

See all geographic segments

Executive Committee: Abbisko Cayman Limited

Manager	Title	Age	Since
Yao Chang Xu CEO	Chief Executive Officer	69	27/03/2018
Hong Ping Yu CTO	Chief Tech/Sci/R&D Officer	58	28/02/2022
Zi Dong Zhang DFI	Director of Finance/CFO	45	15/05/2022
Jia Feng COO	Chief Operating Officer	-	-
Jing Ji CTO	Chief Tech/Sci/R&D Officer	56	31/01/2021

See ABBISKO CAYMAN LIMITED governance

Composition of the Board of Directors: Abbisko Cayman Limited

Director	Title	Age	Since
Yao Chang Xu CHM	Chairman	69	27/03/2018
Hong Ping Yu BRD	Director/Board Member	58	27/03/2018
Piao Yang Sun BRD	Director/Board Member	67	29/09/2021
Hong Bin Sun BRD	Director/Board Member	51	29/09/2021
Jing Ji BRD	Director/Board Member	56	02/03/2025
Hoi Yam Chui BRD	Director/Board Member	58	27/02/2025

Composition of the Board of Directors

Shareholders: Abbisko Cayman Limited

Name	Equities	%	Valuation
Yao Chang Xu 11.77 %	80,034,980	11.77 %	128 M $
LAV Management Co., Ltd. 6.015 %	40,905,790	6.015 %	65 M $
Qiming Venture Partners Ltd. 5.996 %	40,778,906	5.996 %	65 M $
Allianz Global Investors Asia Pacific Ltd. 5.77 %	39,241,000	5.77 %	63 M $
Futu Trustee Ltd. 4.52 %	30,738,202	4.52 %	49 M $

List of ABBISKO CAYMAN LIMITED shareholders

Company details: Abbisko Cayman Limited

Abbisko Cayman Ltd.

898, Building 3

, Shanghai

+86 21 6891 2098

http://www.abbisko.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ABBISKO CAYMAN LIMITED	+4.76%	-6.53%	+48.87%	+293.38%	1.02B
ARGENX SE	-0.61%	-5.35%	+7.61%	+93.47%	44.16B
WUXI APPTEC CO., LTD.	+0.92%	-4.81%	+49.57%	+13.78%	40.5B
INSMED INCORPORATED	-2.40%	-6.16%	+86.79%	+581.90%	30.21B
BIONTECH SE	-0.44%	-7.92%	-8.42%	-22.84%	25.47B
WUXI BIOLOGICS (CAYMAN) INC.	+2.54%	-9.65%	+54.31%	-36.52%	19.22B
GENMAB A/S	-2.62%	-6.49%	+5.33%	-32.35%	16.5B
AKESO, INC.	+5.20%	+0.37%	+49.24%	+146.95%	12.64B
SUMMIT THERAPEUTICS INC.	+1.14%	-8.92%	-20.43%	+987.05%	11.72B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.43%	-0.31%	+53.50%	-	11.51B
Average	+1.29%	-5.22%	+32.64%	+224.98%	21.29B
Weighted average by Cap.	+0.32%	-5.17%	+32.55%	+169.61%